Donidalorsen Treatment in Children With Hereditary Angioedema

计划入组 20 人 · 首次发布于 2025 年 12 月 23 日

OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

计划入组 91 人 · 首次发布于 2021 年 12 月 1 日

A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema

计划入组 23 人 · 首次发布于 2019 年 7 月 24 日

Donidalorsen(Dawnzera)

ticarcillin sodium + sulbactam sodium

Sulbactam sodium/Amoxicillin Sodium

Harbin Medisan Pharmaceutical Co., Ltd .

Hebei Changshan Biochemical Pharmaceutical Co., Ltd

China

Harbin Gloria Pharmaceuticals Co., Ltd.

FDA Approves Three Novel HAE Therapies in 2025, Ending Four-Year Regulatory Drought

FDA Accepts Donidalorsen NDA for Hereditary Angioedema Prophylaxis

FDA Accepts New Drug Application for Donidalorsen for Hereditary Angioedema